Article
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.
Hepatology (Baltimore, Md.) - 1 Apr 2015
Nelson David R, Cooper James N, Lalezari Jacob P, Lawitz Eric, Pockros Paul J, Gitlin Norman, Freilich Bradley F, Younes Ziad H, Harlan William, Ghalib Reem, Oguchi Godson, Thuluvath Paul J, Ortiz-Lasanta Grisell, Rabinovitz Mordechai, Bernstein David, Bennett Michael, Hawkins Trevor, Ravendhran Natarajan, Sheikh Aasim M, Varunok Peter, Kowdley Kris V, Hennicken Delphine, McPhee Fiona, Rana Khurram, Hughes Eric A
Abstract excerpt
UNLABELLED: Treatment options for patients with hepatitis C virus (HCV) genotype 3 infection are limited, with the currently approved all-oral regimens requiring 24-week treatment and the addition of ribavirin (RBV). This phase III study (ALLY-3; ClinicalTrials.gov: NCT02032901) evaluated the 12-week regimen of daclatasvir (DCV; pangenotypic nonstructural protein [NS]5A inhibitor) plus sofosbuvir (SOF;...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.